Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Its more medically complex than general weight counseling and requires coordination with prescribing providers
PMID 25869809)Tier 1 primary [4]Eric Topol, Ground Truths: The Peptide Craze (July 2025) - ipamorelin flagged for cancer risk on IGF-1 groundsTier 2 expert [5]FDA Pharmacy Compounding Advisory Committee meeting, 29 October 2024 (reviewed ipamorelin 503A eligibility)Tier 1 primary No revisions yet
A 2024 retrospective cohort analysis published in Diabetes, Obesity and Metabolism (N=312 patients who switched from semaglutide to tirzepatide at a single academic center) found that switchers lost an additional mean of 6.3% of body weight over 6 months after the switch, with 68% reporting either stable or improved GI tolerability [12]
DOI: 10.1097/MCG.0000000000000814
US$ 28.18
US$ 29.50
US$ 24.28
US$ 25.38
